SteelPeak Wealth LLC Sells 14,754 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

SteelPeak Wealth LLC trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXFree Report) by 16.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,520 shares of the company’s stock after selling 14,754 shares during the quarter. SteelPeak Wealth LLC’s holdings in Recursion Pharmaceuticals were worth $497,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter worth $25,000. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $26,000. GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares during the period. Farther Finance Advisors LLC boosted its stake in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the topic of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th.

View Our Latest Stock Report on RXRX

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the transaction, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.75% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Trading Up 7.4 %

NASDAQ:RXRX opened at $7.69 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The stock’s fifty day moving average price is $7.00 and its two-hundred day moving average price is $6.94. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market cap of $3.00 billion, a P/E ratio of -5.03 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the business earned ($0.43) EPS. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Recursion Pharmaceuticals Profile

(Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Articles

Institutional Ownership by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.